Literature DB >> 10323380

On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism.

D W Dempster1, M Parisien, S J Silverberg, X G Liang, M Schnitzer, V Shen, E Shane, D B Kimmel, R Recker, R Lindsay, J P Bilezikian.   

Abstract

Several studies have demonstrated that cancellous bone mass and architecture are preserved in postmenopausal women with primary hyperparathyroidism (PHPT). To investigate the mechanism(s) that could account for this observation, we analyzed features of bone formation in 19 postmenopausal women with PHPT by bone histomorphometry. The results were compared with those from a comparable group of 34 healthy, postmenopausal women. Patients with PHPT were similar to control subjects in cancellous bone area as well as in trabecular width, separation, and number. However, in PHPT, elevations were observed in indexes of bone turnover, such as eroded surface, osteoid surface, mineralizing surface, bone formation rate at the tissue level, and activation frequency. At the level of the bone-remodeling unit, women with PHPT had significantly higher values for the wall width of trabecular bone packets (40.26 +/- 0.36 vs. 34.58 +/- 0.45 mm), the adjusted apposition rate (0.40 +/- 0.04 vs. 0.29 +/- 0.03 mm/day), and the active formation period (67.8 +/- 5.1 vs. 57.3 +/- 2.3 days). These findings are consistent with a stimulatory action of elevated PTH levels on the duration of the active bone formation phase in individual remodeling units and may account at least in part for the preservation of cancellous bone in postmenopausal women with mild PHPT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323380     DOI: 10.1210/jcem.84.5.5652

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  50 in total

Review 1.  Clinical spectrum of primary hyperparathyroidism.

Authors:  J P Bilezikian; S J Silverberg
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  A case of primary hyperparathyroidism with marked changes in bone mineral density and geometry after parathyroidectomy.

Authors:  Hiroshi Kaji; Mei-Fway Iu; Junko Naito; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 3.  Surgical treatment of obesity.

Authors:  Nancy Puzziferri; Jeanne Blankenship; Bruce M Wolfe
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

4.  Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology.

Authors:  Cristiana Cipriani; Federica Biamonte; Aline G Costa; Chiyuan Zhang; Piergianni Biondi; Daniele Diacinti; Jessica Pepe; Sara Piemonte; Alfredo Scillitani; Salvatore Minisola; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2015-02-03       Impact factor: 5.958

Review 5.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

Review 7.  Endocrine regulation of bone and energy metabolism in hibernating mammals.

Authors:  Alison H Doherty; Gregory L Florant; Seth W Donahue
Journal:  Integr Comp Biol       Date:  2014-02-19       Impact factor: 3.326

8.  The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.

Authors:  Teruyo Nakatani; Tiffany Chen; Joshua Johnson; Jennifer J Westendorf; Nicola C Partridge
Journal:  J Bone Miner Res       Date:  2018-04-25       Impact factor: 6.741

9.  Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.

Authors:  V Camozzi; F Lumachi; F Mantero; M Piccolo; G Luisetto
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

10.  Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Authors:  R A Wermers; C P Recknor; F Cosman; L Xie; E V Glass; J H Krege
Journal:  Osteoporos Int       Date:  2008-02-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.